6
Sep
2023

Freeing the Biotech Founders: Zach Weinberg and Alexis Borisy on The Long Run

Today there are two guests on The Long Run: Zach Weinberg and Alexis Borisy.

Zach Weinberg, co-founder, CEO, Curie Bio

They are co-founders of Curie.Bio.

Curie is a venture capital fund with $520 million, mostly for seed investments and Series A rounds in biotech startups. It also is also building up in-house R&D expertise which it uses to help the entrepreneurs it backs.

Curie pitches itself as different from other venture firms partly because it allows the CEO/founders it backs to hold onto a greater percentage of ownership than traditional VCs have been willing to hand over. Curie also says it wants to allow entrepreneurs to retain more control over decision-making. This boils down to a battle cry of ‘Free the Founders.’

Alexis Borisy, co-founder, operating chairman, Curie Bio

They are tapping into the zeitgeist. Many biotech entrepreneurs feel they sweat bullets for years, shouldering too much of the hard work and risk, without reaping enough of the rewards.

It’s still early days for Curie Bio, but this is conversation worth having about the terms of engagement in biotech startups.

Now, before we get started, a word from the sponsors.

You want your biopharmaceutical or device to go to market as fast as possible because you know it can improve lives. But, statistically speaking, low patient enrollment is going to stop your trial in its tracks. Elligo Health Research® is the ultimate patient provider, giving you immediate access to known, diverse patients from more than 115 hospitals and major health systems, 200 healthcare-based sites, and 100 research-based sites. No endless searching, no waiting.

Visit ElligoHealthResearch.com to get started.

 

One of the most respected, independent investor events is returning to San Francisco! In person for the first time since 2019, the BIO Investor Forum will be held on October 17th and 18th at the Hilton San Francisco Union Square. The conference showcases drug development programs that are ready for partnering or venture funding.

Enjoy limitless networking, on-point sessions crafted by impressive industry experts, polished company presentations, and making important connections powered by BIO One-on-One PartneringTM.

Register Now at bio.org/bif

 

Now, please join me and Zach Weinberg and Alexis Borisy on The Long Run.

You may also like

CRISPR to Protect the Bone Marrow & Attack Cancer: Robert Ang on The Long Run
Gene Expression In Therapeutic R&D: Rick Young on The Long Run
Investing in Healthy Aging: Jens Eckstein on The Long Run
Bispecific Antibodies for Cancer: Shelley Force Aldred and Nathan Trinklein on The Long Run